Evolva Holding SA (EVE) - Net Assets

Latest as of June 2025: CHF6.24 Million CHF ≈ $7.88 Million USD

Based on the latest financial reports, Evolva Holding SA (EVE) has net assets worth CHF6.24 Million CHF (≈ $7.88 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF7.08 Million ≈ $8.96 Million USD) and total liabilities (CHF849.50K ≈ $1.07 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Evolva Holding SA liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets CHF6.24 Million
% of Total Assets 88.01%
Annual Growth Rate -14.55%
5-Year Change -95.45%
10-Year Change -96.76%
Growth Volatility 64.0

Evolva Holding SA - Net Assets Trend (2005–2024)

This chart illustrates how Evolva Holding SA's net assets have evolved over time, based on quarterly financial data. Also explore EVE current and non-current assets for the complete picture of this company's asset base.

Annual Net Assets for Evolva Holding SA (2005–2024)

The table below shows the annual net assets of Evolva Holding SA from 2005 to 2024. For live valuation and market cap data, see EVE company net worth.

Year Net Assets Change
2024-12-31 CHF6.60 Million
≈ $8.34 Million
+18.80%
2023-12-31 CHF5.55 Million
≈ $7.02 Million
-94.77%
2022-12-31 CHF106.24 Million
≈ $134.31 Million
-19.38%
2021-12-31 CHF131.77 Million
≈ $166.59 Million
-9.18%
2020-12-31 CHF145.09 Million
≈ $183.44 Million
-15.92%
2019-12-31 CHF172.56 Million
≈ $218.17 Million
-11.12%
2018-12-31 CHF194.16 Million
≈ $245.47 Million
-12.03%
2017-12-31 CHF220.72 Million
≈ $279.05 Million
+27.54%
2016-12-31 CHF173.06 Million
≈ $218.79 Million
-14.92%
2015-12-31 CHF203.42 Million
≈ $257.17 Million
+16.24%
2014-12-31 CHF174.99 Million
≈ $221.24 Million
+110.13%
2013-12-31 CHF83.28 Million
≈ $105.29 Million
+35.99%
2012-12-31 CHF61.24 Million
≈ $77.42 Million
-16.36%
2011-12-31 CHF73.22 Million
≈ $92.57 Million
+38.23%
2010-12-31 CHF52.97 Million
≈ $66.97 Million
-22.03%
2009-12-31 CHF67.93 Million
≈ $85.89 Million
+210.74%
2008-12-31 CHF21.86 Million
≈ $27.64 Million
-67.43%
2007-12-31 CHF67.12 Million
≈ $84.86 Million
+2.51%
2006-12-31 CHF65.48 Million
≈ $82.78 Million
-49.97%
2005-12-31 CHF130.88 Million
≈ $165.47 Million
--

Equity Component Analysis

This analysis shows how different components contribute to Evolva Holding SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 36899722000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock CHF7.23 Million 109.62%
Other Comprehensive Income CHF45.07 Million 683.33%
Other Components CHF429.50 Million 6511.24%
Total Equity CHF6.60 Million 100.00%

Evolva Holding SA Competitors by Market Cap

The table below lists competitors of Evolva Holding SA ranked by their market capitalization.

Company Market Cap
Mountain Lake Acquisition Corp. Right
NASDAQ:MLACR
$7.08 Million
Sentra Food Indonesia Tbk PT
JK:FOOD
$7.08 Million
Tri-Mode System M Bhd
KLSE:0199
$7.09 Million
SCC Holdings Bhd
KLSE:0158
$7.09 Million
Synlogic Inc
NASDAQ:SYBX
$7.08 Million
Vape Holdings Inc
NASDAQ:VAPE
$7.08 Million
Lendway Inc.
NASDAQ:LDWY
$7.07 Million
Atlas Cycles (Haryana) Limited
NSE:ATLASCYCLE
$7.07 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Evolva Holding SA's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 5,552,600 to 6,596,300, a change of 1,043,700 (18.8%).
  • Net income of 1,044,000 contributed positively to equity growth.
  • Share repurchases of 163,100 reduced equity.
  • Other comprehensive income increased equity by 45,074,399.
  • Other factors decreased equity by 44,911,599.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CHF1.04 Million +15.83%
Share Repurchases CHF163.10K -2.47%
Other Comprehensive Income CHF45.07 Million +683.33%
Other Changes CHF-44.91 Million -680.86%
Total Change CHF- 18.80%

Book Value vs Market Value Analysis

This analysis compares Evolva Holding SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.07x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has increased from 0.00x to 1.07x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2005-12-31 CHF1774.36 CHF0.98 x
2006-12-31 CHF775.76 CHF0.98 x
2007-12-31 CHF699.51 CHF0.98 x
2008-12-31 CHF208.51 CHF0.98 x
2009-12-31 CHF199.03 CHF0.98 x
2010-12-31 CHF73.50 CHF0.98 x
2011-12-31 CHF89.47 CHF0.98 x
2012-12-31 CHF69.78 CHF0.98 x
2013-12-31 CHF70.03 CHF0.98 x
2014-12-31 CHF124.32 CHF0.98 x
2015-12-31 CHF119.65 CHF0.98 x
2016-12-31 CHF90.00 CHF0.98 x
2017-12-31 CHF114.47 CHF0.98 x
2018-12-31 CHF62.99 CHF0.98 x
2019-12-31 CHF56.00 CHF0.98 x
2020-12-31 CHF46.10 CHF0.98 x
2021-12-31 CHF37.44 CHF0.98 x
2022-12-31 CHF24.82 CHF0.98 x
2023-12-31 CHF1.03 CHF0.98 x
2024-12-31 CHF0.91 CHF0.98 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Evolva Holding SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 15.83%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.00%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 1.14x
  • Recent ROE (15.83%) is above the historical average (-123.36%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2005 -26.77% 0.00% 0.00x 1.04x CHF-48.13 Million
2006 -110.77% -26513.74% 0.00x 1.28x CHF-79.08 Million
2007 -88.08% -35937.03% 0.00x 1.29x CHF-65.83 Million
2008 -39.62% -2040.98% 0.01x 2.03x CHF-10.85 Million
2009 -14.22% -50.77% 0.20x 1.37x CHF-16.37 Million
2010 -44.88% -125.07% 0.25x 1.45x CHF-28.49 Million
2011 -30.89% -202.64% 0.10x 1.47x CHF-29.72 Million
2012 -26.13% -228.19% 0.08x 1.48x CHF-22.13 Million
2013 -19.49% -180.70% 0.08x 1.30x CHF-23.80 Million
2014 -12.33% -230.02% 0.04x 1.23x CHF-38.67 Million
2015 -15.82% -339.28% 0.04x 1.15x CHF-52.05 Million
2016 -21.02% -411.19% 0.04x 1.16x CHF-53.08 Million
2017 -17.66% -569.26% 0.03x 1.09x CHF-61.05 Million
2018 -15.05% -327.03% 0.04x 1.10x CHF-48.63 Million
2019 -12.54% -186.61% 0.06x 1.11x CHF-38.90 Million
2020 -20.59% -396.10% 0.05x 1.15x CHF-44.38 Million
2021 -31.32% -417.76% 0.06x 1.19x CHF-54.44 Million
2022 -40.82% -279.08% 0.12x 1.23x CHF-53.99 Million
2023 -1895.13% -1114.95% 0.96x 1.77x CHF-105.78 Million
2024 15.83% 0.00% 0.00x 1.14x CHF384.37K

Industry Comparison

This section compares Evolva Holding SA's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $153,398,342
  • Average return on equity (ROE) among peers: -34.58%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Evolva Holding SA (EVE) CHF6.24 Million -26.77% 0.14x $7.08 Million
Addex Therapeutics Ltd (ADXN) $33.84 Million -92.04% 0.29x $7.10 Million
BB Biotech AG (BION) $1.91 Billion 10.59% 0.00x $2.25 Billion
Basilea Pharmaceutica AG (BSLN) $125.38 Million -47.04% 0.20x $699.48 Million
Idorsia Ltd (IDIA) $-1.21 Billion 0.00% 0.00x $759.27 Million
Molecular Partners AG (MOLN) $135.79 Million -13.71% 0.36x $145.86 Million
Newron Pharmaceuticals SpA (NWRN) $29.28 Million -80.19% 0.42x $360.88 Million
Relief Therapeutics Holding AG (RLF) $14.30 Million -52.18% 0.39x $36.33 Million
Santhera Pharmaceuticals Holding AG (SANN) $104.47 Million -42.74% 0.08x $244.59 Million
Xlife Sciences AG (XLS) $235.23 Million 6.08% 1.08x $122.27 Million

About Evolva Holding SA

SW:EVE Switzerland Biotechnology
Market Cap
$8.94 Million
CHF7.07 Million CHF
Market Cap Rank
#27655 Global
#210 in Switzerland
Share Price
CHF0.98
Change (1 day)
-4.85%
52-Week Range
CHF0.75 - CHF1.33
All Time High
CHF259.80
About

EvoNext Holdings SA is in the process of liquidation of its remaining assets. Previously, the company was engaged in discovery, research, development, and commercialization of nature-based ingredients for use in flavor and fragrances, health ingredients, health protection, and other sectors in Switzerland, the United States, and internationally. The company was formerly known as Evolva Holding SA… Read more